Low-molecular-weight heparins vs vitamin K antagonists for treating blood clots in cancer patients
Author Information
Author(s): Akl Elie A, Barba Maddalena, Rohilla Sandeep, Terrenato Irene, Sperati Francesca, Muti Paola, Schünemann Holger J
Hypothesis
Is low molecular weight heparin more effective than vitamin K antagonists for long-term treatment of venous thromboembolism in cancer patients?
Conclusion
Low molecular weight heparin reduces venous thromboembolism in cancer patients but does not significantly affect mortality compared to vitamin K antagonists.
Supporting Evidence
- Low molecular weight heparin significantly reduced the risk of recurrent venous thromboembolism.
- Mortality rates did not significantly differ between the two treatment groups.
- The quality of evidence for mortality was rated low, while it was moderate for recurrent venous thromboembolism.
Takeaway
This study found that a type of blood thinner called low molecular weight heparin helps prevent blood clots in cancer patients better than another type called vitamin K antagonists, but it doesn't help them live longer.
Methodology
A systematic review of randomized controlled trials comparing low molecular weight heparin and oral anticoagulants for treating venous thromboembolism in cancer patients.
Potential Biases
Potential publication bias was assessed but not indicated in the results.
Limitations
The review could not include data from 11 eligible RCTs with cancer patients due to unavailability of relevant data.
Participant Demographics
Patients with cancer diagnosed with venous thromboembolism.
Statistical Information
P-Value
0.003
Confidence Interval
95% CI 0.32 to 0.71
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website